Please check your internet connection and try again.
# Isoxsuprine hydrochloride
## Overview
Isoxsuprine hydrochloride is a peripheral vasodilator with beta-adrenergic agonist activity. Its exact mechanism of action in improving peripheral circulation is not fully understood, but it is thought to cause direct relaxation of vascular smooth muscle and may have some effect on beta-receptors.
## Primary Indications
* Treatment of peripheral vascular diseases such as arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease), and Raynaud's disease.
* Relief of vasospasm and related symptoms in peripheral vascular diseases.
## Adult Dosing
* **Oral:** The usual adult dose is 10-20 mg by mouth every 3-4 times daily.
* **Maximum dose:** Not specifically established, but higher doses are generally not associated with increased efficacy and may increase the risk of adverse effects.
## Pediatric Dosing
* No established pediatric dosing. Use is generally not recommended in children.
## Dose Adjustments
* No specific dose adjustments are routinely recommended for renal or hepatic impairment. However, caution is advised in patients with severe impairment due to potential for decreased metabolism and excretion.
## Contraindications
* Hypersensitivity to isoxsuprine.
* Should not be administered intravascularly (IV administration has resulted in serious adverse events).
* Patients with cardiac arrhythmias or in whom cardiac rhythm is a concern.
## Adverse Effects
* **Common:** Nausea, vomiting, stomach upset, dizziness, weakness, flushing, headache, hypotension, rash.
* **Less Common:** Tachycardia, palpitations, abdominal distress, drowsiness, nervousness.
* **Rare:** Hypotension can be severe.
## Key Drug Interactions
* **Antihypertensives:** Isoxsuprine may potentiate the effects of antihypertensive medications, leading to additive hypotension.
* **Other vasodilators:** Concomitant use may lead to excessive vasodilation and hypotension.
## Monitoring
* Blood pressure: Monitor for hypotension, especially at the start of therapy or with dose increases.
* Cardiac rhythm: Assess for tachycardia or palpitations.
* Symptoms of peripheral vascular disease: Evaluate for improvement in claudication, skin temperature, or color.
## Clinical Pearls
* Efficacy in improving peripheral circulation is controversial and clinical data supporting its widespread use is limited.
* Oral administration is the only recommended route; avoid IV administration.
* Patients should be advised to rise slowly from a sitting or lying position to minimize the risk of orthostatic hypotension.
* Effectiveness may take several weeks to become apparent.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and clinical guidelines before making treatment decisions.*
